查詢結果分析
相關文獻
- 子宮頸癌高劑量率與低劑量率體腔內近接治療之現況與比較
- 子宮頸癌放射治療的結果及直腸後遺症的分析(新光醫院的五年經驗)
- High-Dose-Rate Afterloading Brachytherapy in Carcinoma of the Uterine Cervix
- Survival Advantages and Complications of Adjuvant Therapy in Early-Stage Cervical Cancer with Pelvic Node Metastasis
- Clinincal Characteristics and Management of Enterovesical Fistulas
- Well-Differentiated Papillary Villoglandular Adenocarcinoma of the Uterine Cervix: A Case Report
- 以皮膚穴道電機能篩檢儀對婦科腫瘤病人治療前後及恢復期之觀察
- Calibration of High Dose Rate Source Activity
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- 推展婦女子宮頸癌防治工作策略與成果
頁籤選單縮合
題 名 | 子宮頸癌高劑量率與低劑量率體腔內近接治療之現況與比較=Current Status and Comparison of High-Dose-Rate (HDR) vs. Low-Dose-Rate (LDR) Intracavitary Brachytherapy in Treatment of Cervical Carcinoma |
---|---|
作 者 | 王重榮; 梁雲; 陳惠君; 孫立民; 方富民; | 書刊名 | 放射治療與腫瘤學 |
卷 期 | 4:3 1997.09[民86.09] |
頁 次 | 頁237-241 |
分類號 | 417.2832 |
關鍵詞 | 體腔內近接治療; 高劑量率; 子宮頸癌; Intracavitary brachytherapy; High-dose-rate; Cervical carcinoma; |
語 文 | 中文(Chinese) |
中文摘要 | 子宮頸癌體腔內近接治療的技術與趨勢, 在過去的十年有極顯著的轉變:高劑量 率( HDR )技術正逐漸的取代過去使用近半世紀的低劑量率( LDR )技術。臨床的報告顯 示,HDR 的結果與 LDR 相當、或比 LDR 略好,更重要的是嚴重的併發症有明顯的減少。這 其中必須歸因於 HDR 射源的改進與電子機械設備的現代化, 以及 HDR 適當的分次治療。 HDR 與 LDR 的隨機比較、最適當分次原則、直腸併發症的減少是 HDR 將來重要的議題。 |
英文摘要 | Over the past one decade, there was a significant reverse in clinical attitude to the high-dose-rate (HDR) intracavitary brachytherapy for treatment of cervical carcinoma. Cumulative data from both meta-analysis and a few available randomized studies have shown that results of HDR were comparable with, or slightly superior to, that of the existing low-dose-rate (LDR) results. The improvement of treatment results, parallel with a significant reduction of severe rectal complication rate (Grade 3 and 4), has been attributed mainly to the improved physical/mechanical characteristics of HDR facility and the use of appropriately fractionated treatment. Prospective randominzed comparison of HDR vs. LDR, optimal dose-fractionation study, and prediction/prevention of rectal complication are the three central issues of HDR in the future. |
本系統中英文摘要資訊取自各篇刊載內容。